Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals

Conclusion: The de novo HCC rates did not differ between the DAA-treated patients and those who received IFN. Achievement of SVR is of utmost importance for HCC prevention.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research